Alphabet-backed start-up Isomorphic Labs has added another name to the roster of pharma companies tapping into its AI-based drug discovery engine. Johnson & Johnson's Janssen Biotech unit is the ...

Isomorphic Lab’s AlphaFold 3 system, developed with Google DeepMind, won its developers a Nobel Prize. Image credit: Shutterstock / Robert Way Alphabet’s AI drug development subsidiary Isomorphic Labs ...

Isomorphic Labs, a Deepmind spin-off focused on drug discovery, is getting ready for its first clinical trials with drugs designed using AlphaFold-based AI models. "We're staffing up now. We're ...

Add Yahoo as a preferred source to see more of our stories on Google. In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

It is an extendable isomorphic log sending library written in TypeScript for javascript applications in nodejs and browsers for reporting data (logs) to remote log storages like SumoLogic, Loggly and ...

Isomorphic Labs was spun out of Google DeepMind, after the tech giant achieved one of the biggest biological breakthroughs in the last 50 years. Demis Hassabis is at the helm of both Isomorphic and ...

On a rare sunny day in London at the Google DeepMind office, Colin Murdoch saw the bank deposit from his employer come through. It wasn't his paycheck. Google was investing in his startup. The ...

Turns out AI can be used for more than Ghibli-ifying selfies. AI drug developer Isomorphic Labs raised $600 million in its first external funding round as hype builds around AI-powered biotech.

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital, with ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led the ...